Helga joined Brandon Capital in 2018.
Before joining Brandon Capital, Helga was part of the founding team of portfolio company Respirion Pharmaceuticals, a spinout from The Kids Research Institute Australia, developing a novel treatment for respiratory disease. Previously Helga worked with anti-infective medical devices and effectiveness of respiratory medicines in Cambridge, UK. She is a director of Respirion Pharmaceuticals and board observer of OncoRes Medical and Azura Ophthalmics.
Helga has a Bachelor and Masters in Chemical Engineering and Biotechnology from the Technical University of Denmark, a PhD in Microbiology from the University of Cambridge and has conducted postdoctoral research in bacterial genetics at Imperial College London. She is a Graduate of the Australian Institute of Company Directors, a director of the Cancer Research Trust and an independent governor of the Forrest Research Foundation.
